Fig. 6.

sGC inhibitor treatment decreases PCa tumor growth in vivo. a, b Male mice bearing VCaP xenograft tumors (N = 8) were treated with vehicle or NS2028 (25 mg/kg) through daily intraperitoneal injection. a Tumor growth was measured at indicated time points and b Intratumoral cGMP levels were measured in tumor biopsies at 19d. c–e Male mice bearing VCaP xenograft tumors (N = 6) were treated daily with vehicle, NS2028 alone (50 mg/kg), enzalutamide alone (10 mg/kg), or in combination. c Tumor growth was measured at indicated time points, d the expression of ERG, GUCY1B1, and GUCY1A1 was measured in tumor biopsies at 13d using qRT-PCR, and e Intratumoral cGMP levels were measured using the same group of biopsies. f, g Castrated male mice bearing LuCaP35CR xenograft tumors (N = 6) were treated daily with vehicle or NS2028 (50 mg/kg). f Tumor growth was measured at indicated time points and g intratumoral cGMP levels were measured in tumor biopsies at 19d